Abiraterone --- CYP17 inhibitor Abiraterone (CB-7598)
| Overview | |
| Catalog # | bs-60031c-10mg-solid |
| Product Name | Abiraterone --- CYP17 inhibitor Abiraterone (CB-7598) |
| Specifications | |
| Storage Buffer | Powder |
| Storage Condition | Store in dry, dark place at -20C for 1 year. |
| Target | |
| Product Information | Molecular Weight: 349.51 Formula: C24 H31 N O CAS Number: 154229-19-3 InChi Key: GZOSMCIZMLWJML-VJLLXTKPSA-N InChi: InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1 Smiles: C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2C1C=NC=CC=1 Purity: 98.0 Solubility: DMSO up to 20mM Appearance: Solid Power. Shelf Life: 1.0 years |
| Description | Abiraterone is the first-in-class potent and selective CYP17 (cytochrome P450 17alpha-hydroxylase-17, 20-lyase) inhibitor with IC50 ~4 nM. It was approved by US FDA in 2011 to treat castration-resistant prostate cancer. As prostate cancer cells proliferate in response to androgen steroids, CYP17 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic prostate cancer. In recent Nature publication, the structures of cytochrome P450 17A1 with abiraterone was released. A phase I/II clinical trial evaluating abiraterone in advanced breast cancer patients is also underway. |
Powered by Bioz